NEW DATA ON IMMUNOMEDICS’ CANCER THERAPEUTICS TO BE PRESENTED AT 40TH ANNUAL MEETING OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO)

Morris Plains, NJ, June 3, 2004 - Immunomedics, Inc. (Nasdaq:IMMU) today announced that 7 presentations are scheduled at the ASCO meeting in New Orleans from June 5-8, 2004. These include the following:

Abstract 6579 - Leukemia, Lymphoma and Transplantation Session, Sunday, June 6, 2004, 8:00 am -12:00 pm. Multi-centre, phase II study of combination antibody therapy with epratuzumab plus rituximab in relapsed/refractory indolent and aggressive NHL: Promising clinical results.

Abstract 6580 - Leukemia, Lymphoma and Transplantation Session, Sunday, June 6, 2004, 8:00 am - 12:00 pm. Initial results of a pilot study of epratuzumab and rituximab in combination with CHOP chemotherapy (ER-CHOP) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL).

Abstract 6535 - Leukemia, Lymphoma and Transplantation Session, Sunday, June 6, 2004, 1:00 pm -5:00 pm. Therapeutic activity of a new antibody-drug immunoconjugate, IMMU-110, in preclinical studies targeted against multiple myeloma.

Abstract 2545 - Developmental Therapeutics: Immunotherapy Session, Monday, June 7, 2004, 8:00 am -12:00 pm. Radioimmunotherapy in non-Hodgkin's lymphoma (NHL) using a fractionated schedule of DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab.

Abstract 2555 - Developmental Therapeutics: Immunotherapy Session, Monday, June 7, 2004, 8:00 am -12:00 pm. Therapeutic effects of anti-CEA (CEACAM5) and anti-NCA90 (CEACAM6) antibody monovalent fragments in vitro and in vivo.


Immunomedics is a biopharmaceutical company focused on the development, manufacture and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer and other serious diseases. Integral to these products are highly specific monoclonal antibodies and antibody fragments designed to
deliver radioisotopes and chemotherapeutic agents to tumors and other sites of disease. Immunomedics has nine therapeutic product candidates in clinical development and has two marketed diagnostic imaging products. The most advanced therapeutic product candidates are LymphoCide® (epratuzumab), for which certain Phase II clinical trials for the treatment of non-Hodgkin’s lymphoma have already been completed, and CEA-Cide® (labetuzumab), which is in Phase I/II clinical trials for the treatment of certain solid tumors.

This release, in addition to historical information, contains forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), competitive risks to marketed products and availability of financing and other sources of capital, as well as the risks discussed in the Company’s Annual Report on Form 10-K for the year June 30, 2003. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.